









Markets
/
Stocks
/
nasdaq-ncna
/

NuCana PLC

NCNA

View Detailed Chart

0.043USD

+0.004+9.97%

Market hours （ET）Quotes delayed by 15 min

261.31KMarket Cap

LossP/E TTM



NuCana PLC

0.043

+0.004+9.97%

Overview Company Financials

Financials

Intraday

30m

Today

+9.97%

5 Days

-27.85%

1 Month

-19.78%

6 Months

-95.57%

Year to Date

-96.39%

1 Year

-98.78%

View Detailed Chart

Agency Rating

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

15m

30m

15m

30m

D

Sell

Sell(9)

Neutral(2)

Buy(0)

Indicators

Sell(3)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

0.005

Neutral

RSI(14)

36.181

Neutral

STOCH(KDJ)(9,3,3)

15.957

Sell

ATR(14)

0.007

Low Volatility

CCI(14)

-184.241

Sell

Williams %R

87.205

Oversold

TRIX(12,20)

-2.023

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

0.047

Sell

MA10

0.050

Sell

MA20

0.051

Sell

MA50

0.066

Sell

MA100

0.354

Sell

MA200

0.813

Sell

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The Company's pipeline includes NUC-3373, and NUC-7738. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil (5-FU). 5-FU is a prescribed anti-cancer agent. NUC-3373 has been evaluated in a Phase I clinical trial for patients with advanced solid tumors and is under Phase Ib/II clinical trial for patients with advanced colorectal cancer. NUC-7738 is a ProTide transformation of a nucleoside analog, 3’-deoxyadenosine (3’-Da). The Company is evaluating NUC-7738 in a Phase I/II clinical trial for patients with advanced solid tumors. Its pipeline also includes Acelari, which is a ProTide transformation of the nucleoside analog gemcitabine. The Company’s subsidiaries include NuCana, Inc., NuCana Limited and NuCana BioMed Trustee Company Limited.

Ticker SymbolNCNA

CompanyNuCana PLC

CEO

Websitehttps://www.nucana.com/